Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alpha-fluoro-substituted thalidomide analogues.

Hon-Wah Man1, Laura G Corral, David I Stirling

  • 1Celgene Corporation, Warren, NJ 07059, USA. hwman@celgene.com

Bioorganic & Medicinal Chemistry Letters
|September 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted protein degradation of PDE4 shortforms by a novel proteolysis targeting chimera.

The FEBS journal·2024
Same author

The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance.

Journal of molecular medicine (Berlin, Germany)·2020
Same author

A novel fibroblast activation inhibitor attenuates left ventricular remodeling and preserves cardiac function in heart failure.

American journal of physiology. Heart and circulatory physiology·2018
Same author

A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.

Journal of medicinal chemistry·2017
Same author

Protein Degradation via CRL4<sup>CRBN</sup> Ubiquitin Ligase: Discovery and Structure-Activity Relationships of Novel Glutarimide Analogs That Promote Degradation of Aiolos and/or GSPT1.

Journal of medicinal chemistry·2017
Same author

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.

Blood·2015

Thalidomide analogues were synthesized to improve its anti-cancer properties. Alpha-fluoro-4-aminothalidomide demonstrated significantly enhanced inhibition of tumor necrosis factor-alpha (TNF-alpha) without toxicity.

Area of Science:

  • Medicinal Chemistry
  • Immunology
  • Pharmacology

Background:

  • Thalidomide, initially a sedative with teratogenic effects, is now recognized for its anti-cancer benefits by inhibiting tumor necrosis factor-alpha (TNF-alpha).
  • Thalidomide's chiral instability raises questions about isomer-specific biological activities.
  • Developing chirally stable analogues is crucial for optimizing therapeutic potential.

Purpose of the Study:

  • To synthesize chirally stable thalidomide analogues.
  • To evaluate the TNF-alpha inhibitory and cytotoxic properties of these new compounds.

Main Methods:

  • Electrophilic fluorination was used to prepare alpha-fluorothalidomide and alpha-fluoro-4-aminothalidomide.
  • Cytotoxicity was assessed in human peripheral blood mononuclear cells (hPBMCs).

Related Experiment Videos

  • TNF-alpha inhibition was measured in lipopolysaccharide (LPS)-stimulated hPBMCs.

    • Main Results:

    • Alpha-fluorothalidomide exhibited cytotoxicity and failed to inhibit TNF-alpha at non-toxic concentrations.
    • Alpha-fluoro-4-aminothalidomide was non-cytotoxic and showed 830-fold greater potency in inhibiting TNF-alpha compared to thalidomide.
    • This highlights significant differences in biological activity between the synthesized analogues.

    Conclusions:

    • Alpha-fluoro-4-aminothalidomide represents a promising, potent, and non-toxic TNF-alpha inhibitor.
    • This analogue holds potential for improved cancer therapy by leveraging enhanced anti-inflammatory and anti-cancer mechanisms.
    • Chirally stable analogues offer a pathway to refine thalidomide's therapeutic applications.